Publikasi Scopus FKUI 2021 per tanggal 31 Juli 2021 (507 artikel)

Krisandi G., Arfandi H., Karina K., Rosadi I.
57225009844;57225008640;57212146678;57204720098;
Primary advanced stage non-smoking human lung cancer peripheral blood mononuclear cells count
2021
Teikyo Medical Journal
44
2
625
632
Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; School of Medicine and Health Sciences, Atma Jaya Catholic University, Jakarta, Indonesia; HayandraLab, Yayasan Hayandra Peduli, Jakarta, Indonesia; Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia; Faculty of Medicine, Universitas Pembangunan Nasional Veteran Jakarta, Jakarta, Indonesia; Department of Biology, Faculty of Mathematics and Natural Sciences, Mulawarman University, Samarinda, Indonesia
Krisandi, G., Faculty of Medicine, University of Indonesia, Jakarta, Indonesia, HayandraLab, Yayasan Hayandra Peduli, Jakarta, Indonesia; Arfandi, H., School of Medicine and Health Sciences, Atma Jaya Catholic University, Jakarta, Indonesia, HayandraLab, Yayasan Hayandra Peduli, Jakarta, Indonesia; Karina, K., HayandraLab, Yayasan Hayandra Peduli, Jakarta, Indonesia, Klinik Hayandra, Yayasan Hayandra Peduli, Jakarta, Indonesia, Faculty of Medicine, Universitas Pembangunan Nasional Veteran Jakarta, Jakarta, Indonesia; Rosadi, I., HayandraLab, Yayasan Hayandra Peduli, Jakarta, Indonesia, Department of Biology, Faculty of Mathematics and Natural Sciences, Mulawarman University, Samarinda, Indonesia
Lung cancer is found to cause the inactivation of cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells which are mostly found in the peripheral blood mononuclear cells (PBMC) and prevent host resistance to lung cancer growth. Thus, by knowing whether there is a decrease in PBMC count in lung cancer patients, immune cell therapy can be considered to increase host resistance towards lung cancer growth. PBMC samples from 3 lung cancer patients and 3 non-lung cancer patients were taken from Klinik Hayandra database with patient’s informed consent. PBMC were then counted and calculated for their viability and proportion with Trypan Blue Staining. PBMC proportion is significantly lower (p=0.002) in lung cancer patients (402,500) than patients without lung cancer (1,465,000). PBMC viability is significantly lower (p=0.015) in lung cancer patients (95.97%) than control group (98.84%). A significant decrease was found in both PBMC proportion and viability in patients with lung cancer than the control group. © 2021 Teikyo University School of Medicine. All rights reserved.
Advanced stage human lung cancer; PBMC count; Peripheral blood mononuclear cells
Teikyo University School of Medicine
3875547
Article
Q4
100
32543